DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
02/02/2024* 07:00 EST Earnings Call Q4 2023 -- -- --
07/27/2023 -- Results Q2 2023 -- -- --
02/02/2023 -- Results Q4 2022 -- -- --
02/02/2023 01:00 EST Earnings Call Q4 2022 -- -- --
07/21/2022 -- Results Q2 2022 -- -- --
02/03/2022 01:00 EST Earnings Call Q4 2021 -- -- --
02/03/2022 -- Results Q4 2021 -- -- --
07/27/2021 -- Results Q2 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 07/27/2023
EPS Estimate Upgrade
Last Actual EPS Upgrade
 
4.00
2.00
1.00
 
Q2 '20
Q3 '20
Q4 '20
Q1 '21
Q2 '21
No data available
Last Report Date 02/02/2023
Beat/Miss Upgrade
Return Since -2.51%
Last FQE 06/30/2022
Next FQE 09/30/2022

Profile

Edit
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's best-selling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
URL https://www.roche.com
Investor Relations URL https://www.roche.com/investors.htm
HQ State/Province N/A
Sector Healthcare
Industry Drug Manufacturers - General
Equity Style Large Cap/Blend
Next Earnings Release Jul. 27, 2023
Last Earnings Release Feb. 02, 2023
Next Ex-Dividend Date N/A
Last Ex-Dividend Date Mar. 16, 2023

Dividends

Dividend Per Share (TTM) 9.637
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 2.566
Yield to Sector 1.706
Yield to Industry 0.9098
Last Dividend Amt. 10.20
Dividend Frequency Annually
Last Ex-Dividend Date Mar. 16, 2023
Yield (TTM) 3.60%
Forward Yield 3.59%
Payout Ratio 49.82%
Cash Payout Ratio 40.74%
Consistent Payer (5Y) Yes
Consistent Growth (5Y) Yes

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Annual Total Returns Versus Peers

Loading chart...
Name
2016
2017
2018
2019
2020
2021
2022
YTD
-14.16%
13.68%
-1.16%
34.57%
4.82%
23.40%
-21.36%
-5.68%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-18.11%
4.67%
--
-1.39%
-26.17%
-9.84%
-39.32%
-4.26%
-58.79%
7.84%
--
15.89%
21.68%
113.2%
151.4%
-50.51%
-46.36%
10.85%
--
--
29.71%
-69.83%
-45.55%
-4.33%
-92.71%
-16.90%
--
--
--
--
--
-53.06%
-89.98%
84.10%
As of March 21, 2023.

Profile

Edit
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's best-selling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
URL https://www.roche.com
Investor Relations URL https://www.roche.com/investors.htm
HQ State/Province N/A
Sector Healthcare
Industry Drug Manufacturers - General
Equity Style Large Cap/Blend
Next Earnings Release Jul. 27, 2023
Last Earnings Release Feb. 02, 2023
Next Ex-Dividend Date N/A
Last Ex-Dividend Date Mar. 16, 2023

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
MGRBX 562.76M CHF 4.19%
FIGSX 495.38M CHF 3.61%
MRIBX 430.74M CHF 2.87%
VGK 414.22M CHF 1.84%
FSPSX 551.76M CHF 1.38%
EFA 622.66M CHF 1.35%
IEFA 1.053B CHF 1.16%
VDVIX 1.528B CHF 0.96%
VEA 1.528B CHF 0.96%
VEU 407.60M CHF 0.84%
VTISX 2.636B CHF 0.72%
VXUS 2.636B CHF 0.72%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Nasdaq Insider Trading
Nasdaq Institutional Ownership